These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 21163349)

  • 41. Microtubule stabilization promoted axonal regeneration and functional recovery after spinal root avulsion.
    Li H; Wu W
    Eur J Neurosci; 2017 Jul; 46(1):1650-1662. PubMed ID: 28444817
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies.
    Venkatramani A; Panda D
    Int J Biol Macromol; 2019 Jul; 133():473-483. PubMed ID: 31004638
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice.
    Michaelis ML; Georg G; Telikepalli H; McIntosh M; Rajewski RA
    Curr Alzheimer Res; 2006 Jul; 3(3):215-9. PubMed ID: 16842098
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The microtubule-stabilizing drug Epothilone D increases axonal sprouting following transection injury in vitro.
    Brizuela M; Blizzard CA; Chuckowree JA; Dawkins E; Gasperini RJ; Young KM; Dickson TC
    Mol Cell Neurosci; 2015 May; 66(Pt B):129-40. PubMed ID: 25684676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microtubule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments.
    Trojanowski JQ; Smith AB; Huryn D; Lee VM
    Expert Opin Pharmacother; 2005 May; 6(5):683-6. PubMed ID: 15934894
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.
    Onishi T; Maeda R; Terada M; Sato S; Fujii T; Ito M; Hashikami K; Kawamoto T; Tanaka M
    Sci Rep; 2021 Jul; 11(1):15423. PubMed ID: 34326423
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
    Villanueva C; Dufresne A; Pivot X; Viel E
    Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy.
    Zhang B; Higuchi M; Yoshiyama Y; Ishihara T; Forman MS; Martinez D; Joyce S; Trojanowski JQ; Lee VM
    J Neurosci; 2004 May; 24(19):4657-67. PubMed ID: 15140937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design.
    Xiao Q; Xue T; Shuai W; Wu C; Zhang Z; Zhang T; Zeng S; Sun B; Wang Y
    Biochem Biophys Res Commun; 2021 Jan; 534():330-336. PubMed ID: 33272565
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ixabepilone: a new microtubule-targeting agent for breast cancer.
    Higa GM; Abraham J
    Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform.
    Ishihara T; Hong M; Zhang B; Nakagawa Y; Lee MK; Trojanowski JQ; Lee VM
    Neuron; 1999 Nov; 24(3):751-62. PubMed ID: 10595524
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
    Fojo T; Menefee M
    Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amyloid-beta induced retrograde axonal degeneration in a mouse tauopathy model.
    Nishioka C; Liang HF; Barsamian B; Sun SW
    Neuroimage; 2019 Apr; 189():180-191. PubMed ID: 30630081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
    Badiola N; Suárez-Calvet M; Lleó A
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies.
    Zheng J; Tian N; Liu F; Zhang Y; Su J; Gao Y; Deng M; Wei L; Ye J; Li H; Wang JZ
    Signal Transduct Target Ther; 2021 Jul; 6(1):269. PubMed ID: 34262014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
    Brunden KR; Trojanowski JQ; Lee VM
    Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies.
    Ballatore C; Brunden KR; Trojanowski JQ; Lee VM; Smith AB
    ACS Chem Neurosci; 2017 Jan; 8(1):5-7. PubMed ID: 28095679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stabilization of microtubules restores barrier function after cytokine-induced defects in reconstructed human epidermis.
    Hsu CY; Lecland N; Pendaries V; Viodé C; Redoulès D; Paul C; Merdes A; Simon M; Bierkamp C
    J Dermatol Sci; 2018 Jul; 91(1):87-96. PubMed ID: 29691121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.